


2023 HEDIS[®] Coding & Reference Guide

BCBSKS 2023 QBRP Measures

- 
- 03 CWP** Appropriate Testing for Pharyngitis
 - 05 URI** Appropriate Treatment for Upper Respiratory Infections
 - 07 AAB** Avoidance of Antibiotic Treatment for Bronchitis/Bronchiolitis
 - 09 BCS** Breast Cancer Screening
 - 10 CCS** Cervical Cancer Screening
 - 11 COL** Colorectal Cancer Screening
 - 12 HBD** Hemoglobin A1c Control for Patients with Diabetes
 - 13 EED** Eye Exam for Patients with Diabetes
 - 14 SPC** Statin Therapy for Patients with Cardiovascular Disease
 - 16 SPD** Statin Therapy for Patients with Diabetes
 - 18 LBP** Use of Imaging Studies for Low Back Pain
 - 19 W30** Well-Child Visits in the First 30 Months of Life
 - 20 WCV** Child and Adolescent Well-Care Visits
 - 21** Appendix A: Definitions
 - 22** Appendix B: Changes
 - 23** Appendix C: Supplemental Code Sets – Z Codes and CPT Category II Codes
 - 30** Appendix D: Potential Future Measures
 - 37** Appendix E: Stratification by Race and Ethnicity
 - 38** Disclaimers

Appropriate Testing for Pharyngitis (CWP)



Description

The percentage of episodes for members 3 years and older where the member was diagnosed with pharyngitis, dispensed an antibiotic and received a group A streptococcus (strep) test for the episode.

Eligible Population

Children 3 years of age as of July 1 of the year prior to the measurement year as of June 30 of the measurement year with an Outpatient, Telephone, Online Assessment, Observation or ED visit with only a diagnosis of pharyngitis and a dispensed antibiotic for that episode of care.

Event/Diagnosis

Outpatient, Telephone, Online Assessment, Observation or ED visit with only a diagnosis of pharyngitis and a dispensed antibiotic for that episode of care during Intake Period (12-month window that begins July 1 of the year prior to the measurement year and ends on June 30 of the measurement year).

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population. (Member must have BCBSKS medical and pharmacy benefits)

Numerator

A group A streptococcus test in the seven-day period from three days prior to the Episode Date through three days after the Episode Date. Index Episode Start Date.

The earliest Episode Date during the Intake Period that meets all the following criteria:

- Linked to a dispensed antibiotic prescription (Table 1) on or during the three days after the Episode Date.
- A 30-day Negative Medication History prior to the Episode Date.
- The member was continuously enrolled without a gap in coverage during the 30 days prior to the Episode Date through 3 days after the Episode Date.
- This measure is reported as 4 rates:
 - 3-17 years
 - 18-64 years
 - 65 years and older
 - Total

Required Exclusions/ Negative Conditions

- A period of 30 days prior to the episode date, when the member had no pharmacy claims for either new or refill prescriptions for a listed antibiotic drug. No prescriptions that were filled more than 30 days prior to the episode date and are active on the episode date.
- Exclude episode dates if the member did not receive antibiotics on or up to three days after the episode date with only a diagnosis of pharyngitis.
- Exclude visits that result in an inpatient stay
- Members in hospice or using hospice services anytime during the measurement year.
- Negative comorbid condition history: HIV, HIV Type 2, Malignant Neoplasms, Other Malignant Neoplasms of Skin, Emphysema, COPD, Disorders of the Immune System, Comorbid Conditions.
- Members who died any time during the measurement year.

Table 1: Antibiotic Medications (CWP)

Description	Prescription
Aminopenicillins	• Ampicillin • Amoxicillin
Beta-lactamase inhibitors	• Amoxicillin-clavulanate
First generation cephalosporins	• Cefadroxil • Cephalexin • Cefazolin
Folate antagonist	• Trimethoprim
Lincomycin derivatives	• Clindamycin
Macrolides	• Azithromycin • Clarithromycin • Erythromycin
Natural penicillins	• Penicillin G sodium • Penicillin G potassium • Penicillin V potassium • Penicillin G benzathine
Quinolones	• Ciprofloxacin • Levofloxacin • Ofloxacin • Moxifloxacin
Second generation cephalosporins	• Cefaclor • Cefuroxime • Cefprozil
Sulfonamides	• Sulfamethoxazole-trimethoprim
Tetracyclines	• Doxycycline • Tetracycline • Minocycline
Third generation cephalosporins	• Cefdinir • Cefixime • Cefpodoxime • Ceftriaxone

Appropriate Testing for Upper Respiratory Infections (URI)



Description

The percentage of episodes for members 3 months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event.

Calculation

The measure is reported as an inverted rate [$1 - (\text{numerator}/\text{eligible population})$]. A higher rate indicates appropriate URI treatment of children with URI (i.e., the proportion of the episodes that did not result in an antibiotic dispensing event).

Eligible Population

Members 3 months of age as of July 1 of the year prior to June 30 of the measurement year with continuous enrollment (30 days prior to Episode date through 3 days after Episode Date) and an Outpatient, Telephone, Online Assessment, Observation or ED visit with only a diagnosis of URI.

Event/Diagnosis

Identify all members who had an outpatient visit, a telephone visit, an online assessment, an observation visit or an ED visit during the Intake Period, with a diagnosis of URI. Exclude outpatient, ED or observation visits that result in an inpatient stay.

Determine all URI Episode Dates. For each member identified in step 1, determine all outpatient, telephone, online assessments, observation or ED visits with a URI diagnosis.

Test for Negative Medication History. Exclude Episode Dates where a new or refill prescription for an antibiotic medication (Table 3) was filled 30 days prior to the Episode Date or was active on the Episode Date.

Test for Negative Competing Diagnosis. Exclude Episode Dates where the member had a claim/encounter with a competing diagnosis on or three days after the Episode Date. A code from either of the following meets criteria for a competing diagnosis:

- Pharyngitis Value Set.
- Competing Diagnosis Value Set.

Calculate continuous enrollment. The member must be continuously enrolled without a gap in coverage from 30 days prior to the Episode Date through 3 days after the Episode Date (34 total days).

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population (Member must have BCBSK medical and pharmacy benefit)

Numerator

Dispensed prescription for antibiotic medication from the AAB Medications List (Table 2) on or the three days following the IESD.

Required Exclusions/ Negative Conditions

- A period of 30 days prior to the episode date, when the member had no pharmacy claims for either new or refill prescriptions for a listed antibiotic drug. No prescriptions that were filled more than 30 days prior to the episode date and are active on the episode date.
- Exclude members who had claims/encounters with a competing diagnosis within 30 days prior to episode date. Also exclude members who had a competing diagnosis three days following the episode date (Pharyngitis, etc.)
- Exclude members that have had an emergency visit or observation that resulted in an inpatient stay or have a diagnosis of HIV, HIV Type 2, Malignant Neoplasms, Emphysema, COPD, Cystic Fibrosis, Comorbid Conditions (such as Tuberculosis, sickle-cell anemia, etc.), Disorders of the Immune System (such as autoimmune disorders and immunodeficiency disorders), Pharyngitis, or any Competing Diagnosis.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Table 2: Antibiotic Medications (URI)



Description	Prescription
Aminoglycosides	• Amikacin • Streptomycin • Tobramycin • Gentamicin
Aminopenicillins	• Ampicillin • Amoxicillin
Beta-lactamase inhibitors	• Amoxicillin-clavulanate • Piperacillin-tazobactam • Ampicillin-sulbactam
First generation cephalosporins	• Cefadroxil • Cephalexin • Cefazolin
Fourth generation cephalosporins	• Cefepime
Lincomycin derivatives	• Clindamycin • Lincomycin
Macrolides	• Azithromycin • Erythromycin • Clarithromycin
Miscellaneous antibiotics	• Aztreonam • Daptomycin • Vancomycin • Chloramphenicol • Linezolid • Metronidazole • Dalbopristin-quinupristin
Natural penicillins	• Penicillin G benzathine-procaine • Penicillin G procaine • Penicillin G potassium • Penicillin V potassium • Penicillin G sodium • Penicillin G benzathine
Penicillinase-resistant penicillins	• Dicloxacillin • Oxacillin • Nafcillin
Quinolones	• Ciprofloxacin • Levofloxacin • Ofloxacin • Moxifloxacin • Gemifloxacin
Rifamycin derivatives	• Rifampin
Second generation cephalosporins	• Cefaclor • Cefuroxime • Cefprozil • Cefotetan • Cefoxitin
Sulfonamides	• Sulfamethoxazole-trimethoprim • Sulfadiazine
Tetracyclines	• Doxycycline • Tetracycline • Minocycline
Third generation cephalosporins	• Cefdinir • Cefotaxime • Cefpodoxime • Ceftriaxone • Cefixime • Ceftazidime
Urinary Anti-infectives	• Fosfomycin • Nitrofurantoin Macrocrystals-Monohydrate • Trimethoprim • Nitrofurantoin

Avoidance of Antibiotics for Bronchitis/Bronchiolitis (AAB)



Description

The percentage of episodes for members ages 3 months and older with a diagnosis of acute bronchitis/bronchiolitis that did not result in an antibiotic dispensing event.

Calculation

The measure is reported as an inverted rate [1-(numerator/eligible population)]. A higher rate indicates appropriate acute bronchitis/bronchiolitis treatment (i.e., the proportion for episodes that did not result in an antibiotic dispensing event).

Eligible Population

Members 3 months of age and older with a diagnosis of acute bronchitis/bronchiolitis as of July 1 of the year prior to June 30 of the measurement year with continuous enrollment (30 days prior to Episode date through 3 days after Episode Date).

Event/Diagnosis

Identify all members who had an outpatient visit, a telephone visit, an online assessment an observation visit or an ED visit during the Intake Period, with a diagnosis of acute bronchitis/bronchiolitis.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The Eligible Population (Member must have BCBSKS Medical and Pharmacy benefits)

Numerator

Dispensed prescription for antibiotic medication (Table 3) on or the three days following the Index Episode Start Date (IESD- The date of service for any outpatient or ED visit during the intake period with a diagnosis of acute bronchitis).

This measure is reported as 4 rates:

- 3 months-17 years
- 18-64 years
- 65 years and older
- Total

Required Exclusions/ Negative Conditions

- A period of 30 days prior to the episode date, when the member had no pharmacy claims for either new or refill prescriptions for a listed antibiotic drug. No prescriptions that were filled more than 30 days prior to the episode date and are active on the episode date.
- Excludes members who had claims/encounters with a competing diagnosis within 30 days prior to Episode Date. Also exclude members who had a competing diagnosis three days following the Episode Date (Pharyngitis and Competing Diagnosis).
- Exclude members that have had an emergency visit or observation that resulted in an inpatient stay or have a diagnosis of HIV, HIV Type 2, Other Malignant Neoplasms of Skin, Emphysema, COPD, Comorbid Conditions (such as Tuberculosis, sickle-cell anemia, etc.), Disorders of the Immune System (such as autoimmune disorders and immunodeficiency disorders).
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

7 1) Coding may change periodically without notification

Table 3: Antibiotic Medications (AAB)

Description	Prescription
Aminoglycosides	• Amikacin • Streptomycin • Tobramycin • Gentamicin
Aminopenicillins	• Ampicillin • Amoxicillin
Beta-lactamase Inhibitors	• Amoxicillin-clavulanate • Ampicillin-sulbactam • Piperacillin-tazobactam
First-generation Cephalosporins	• Cefadroxil • Cefazolin • Cephalexin
Fourth-generation Cephalosporins	• Cefepime
Lincomycin Derivatives	• Clindamycin • Lincomycin
Macrolides	• Azithromycin • Erythromycin • Clarithromycin
Miscellaneous Antibiotics	• Aztreonam • Chloramphenicol • Dalfopristin-quinupristin • Daptomycin • Linezolid • Metronidazole • Vancomycin
Natural Penicillin	• Penicillin G benzathine-procaine • Penicillin G procaine • Penicillin G potassium • Penicillin V potassium • Penicillin G sodium • Penicillin G benzathine
Penicillinase-resistant penicillins	• Dicloxacillin • Nafcillin • Oxacillin
Quinolones	• Ciprofloxacin • Levofloxacin • Ofloxacin • Moxifloxacin • Gemifloxacin
Rifamycin Derivatives	• Rifampin
Second Generation Cephalosporins	• Cefaclor • Cefotetan • Cefoxitin • Cefprozil • Cefuroxime
Sulfonamides	• Sulfamethoxazole-trimethoprim • Sulfadiazine
Tetracyclines	• Doxycycline • Tetracycline • Minocycline
Third Generation Cephalosporins	• Cefdinir • Cefotaxime • Cefpodoxime • Ceftriaxone • Cefixime • Ceftazidime
Urinary Anti-infectives	• Fosfomycin • Nitrofurantoin • Nitrofurantoin macrocrystals-monohydrate • Trimethoprim

Breast Cancer Screening (BCS-E)



Description

The percentage of women 52-74 years of age who had a mammogram to screen for breast cancer.

Eligible Population

Women 52–74 years of age as of December 31 of the measurement year with continuous enrollment (no more than one enrollment gap of less than 45 days in each full calendar year) from the measurement year and the year prior to the measurement year.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

One or more mammograms any time on or between October 1 two years prior to the measurement year and December 31 of the measurement year.

Required Exclusions/ Negative Conditions

- Exclude members who have had a bilateral mastectomy any time during the member's history through December 31 of the measure year. That includes:
 - Bilateral mastectomy
 - Unilateral mastectomy with a bilateral modifier
 - Clinical Unilateral Mastectomy with a bilateral modifier
 - History of bilateral mastectomy
- For members with a history of mastectomy (Acquired Absence of Bilateral Breast and Nipples) can be documented administratively on claims via ICD-10 code: Z90.13.
- Members receiving palliative care during the measurement year.
- Members in hospice or using hospice services anytime during the measurement year.

Cervical Cancer Screening (CCS)



Description

The percentage of women 21–64 years of age who were screened for cervical cancer using either of the following criteria:

- Women 21–64 years of age who had cervical cytology performed every 3 years.
- Women 30–64 years of age who had cervical high – risk human papillomavirus (hrHPV) co-testing performed every 5 years.
- Women 30–64 years of age who had a cervical cytology/high-risk human papillomavirus (hrHPV) co-testing within the last 5 years

Eligible Population

Women 24–64 years of age as of December 31 of the measurement year with continuous enrollment (no more than one enrollment gap of less than 45 days in each full calendar year) from the measurement year and the two years prior to the measurement year.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

The number of women who were screened for cervical cancer, as identified in steps 1 and 2 below.

- Women 24–64 years of age as of December 31 of the measurement year who had cervical cytology (Cervical Cytology Lab Test; Cervical Cytology Result or Finding) during the measurement year or the two years prior to the measurement year.
- Women 30–64 years of age as of December 31 of the measurement year who had cervical high-risk human papillomavirus (hrHPV) testing (High Risk HPV Lab Test, High Risk HPV Test Result or Finding) during the measurement year or the four years prior to the measurement year and who were 30 years or older on the date of the test.

Required Exclusions/ Negative Conditions

- Exclude members from each eligible population if evidence of hysterectomy with no residual cervix, cervical agenesis or acquired absence of cervix any time during the member's history through December 31 of the measurement year.
- Members receiving palliative care during the measurement year.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Colorectal Cancer Screening (COL)

Description

The percentage of members 45–75 years of age who had appropriate screening for colorectal cancer.

Eligible Population

Members 46–75 years of age as of December 31 of the measurement year with continuous enrollment (no more than one enrollment gap of less than 45 days in each full calendar year) from the measurement year and the year prior to the measurement year.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

One or more screenings for colorectal cancer. Any of the following meet criteria:

- Fecal occult blood test during the measurement year. For administrative data, assume the required number of samples were returned, regardless of FOBT type.
- Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year.
- Colonoscopy during the measurement year or the nine years prior to the measurement year.
- CT colonography during the measurement year or the four years prior to the measurement year.
- Stool DNA with FIT test during the measurement year or the two years prior to the measurement year.

Required Exclusions/ Negative Conditions

- Exclude members from the eligible population if either colorectal cancer or Total Colectomy are included in a member's history through December 31 of the measurement year.
- Members receiving palliative care during the measurement year.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Hemoglobin A1c Control for Patients with Diabetes (HBD)

Description

The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose hemoglobin A1c (HbA1c) was at the following levels during the measurement year:

- HbA1c control (less than 8.0 percent)
- HbA1c poor control (greater than 9.0 percent)

Eligible Population

Members 18–75 years of age as of December 31 of the measurement year, with a diagnosis of diabetes, and continuous enrollment (no more than one enrollment gap of less than 45 days in each full calendar year) in the measurement year.

Event/Diagnosis:

There are two ways to identify members with diabetes: by claim/encounter data and by pharmacy data. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.

Claim/encounter data. Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years):

- At least one acute inpatient encounter with a diagnosis of diabetes without telehealth.
- At least one acute inpatient discharge with a diagnosis of diabetes on the discharge claim. To identify an acute inpatient discharge:
 1. Identify all acute and nonacute inpatient stays.
 2. Exclude nonacute inpatient stays.
 3. Identify the discharge date for the stay.
- At least two outpatient visits, observation visits, telephone visits, online assessments, ED visits, nonacute inpatient encounters or nonacute inpatient discharges (instructions below; the diagnosis must be on the discharge claim), on different dates of service, with a diagnosis of diabetes. Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge:
 1. Identify all acute and nonacute inpatient stays.
 2. Confirm the stay was for nonacute care based on the presence of a nonacute code on the claim.
 3. Identify the discharge date for the stay.

Pharmacy data. Members who were dispensed insulin or hypoglycemic/antihyperglycemic during the measurement year or the year prior to the measurement year.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

An HbA1c test performed during the measurement year, as identified by claim/encounter or automated laboratory data.

Required Exclusions/ Negative Conditions

- Members who do not have a diagnosis of diabetes, in any setting, during the measurement year or the year prior to the measurement year and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes, in any setting, during the measurement year or the year prior to the measurement year.
- Members in hospice or using hospice services anytime during the measurement year.
- Members receiving palliative care during the measurement year.
- Members who died any time during the measurement year.

Eye Exam for Patients with Diabetes (EED)

Description

The percentage of members 18–75 years of age with diabetes (types 1 and 2) who had a retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist).

Eligible Population

Members 18-75 years of age as of December 31 of the measurement year, with a diagnosis of diabetes, and continuous enrollment (no more than one enrollment gap of less than 45 days in each full calendar year) in the measurement year.

Event/Diagnosis

There are two ways to identify members with diabetes: by claim/encounter data and by pharmacy data. The organization must use both methods to identify the eligible population, but a member only needs to be identified by one method to be included in the measure. Members may be identified as having diabetes during the measurement year or the year prior to the measurement year.

Claim/encounter data. Members who met any of the following criteria during the measurement year or the year prior to the measurement year (count services that occur over both years):

At least one acute inpatient encounter with a diagnosis of diabetes without telehealth.

At least one acute inpatient discharge with a diagnosis of diabetes on the discharge claim. To identify an acute inpatient discharge: 1. Identify all acute and nonacute inpatient stays. 2. Exclude nonacute inpatient stays. 3. Identify the discharge date for the stay.

At least two outpatient visits, observation visits, telephone visits, online assessments, ED visits, nonacute inpatient encounters or nonacute inpatient discharges, on different dates of service, with a diagnosis of diabetes. Visit type need not be the same for the two encounters. To identify a nonacute inpatient discharge: 1. Identify all acute and nonacute inpatient stays. 2. Confirm the stay was for nonacute care based on the presence of a nonacute code on the claim. 3. Identify the discharge date for the stay.

Pharmacy data. Members who were dispensed insulin or hypoglycemic/antihyperglycemic on an ambulatory basis during the measurement year or the year prior to the measurement year.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

Any of the following meet the criteria of screening for diabetic retinal eye disease:

- A retinal or dilated eye exam by an eye care professional (optometrist or ophthalmologist)
- A negative retinal or dilated eye exam by an eye care professional in the year prior to the measurement year
- A bilateral eye enucleation anytime during the member's history through December 31 of the measurement year

Required Exclusions/ Negative Conditions

- Members who do not have a diagnosis of diabetes, in any setting, during the measurement year or the year prior to the measurement year and who had a diagnosis of polycystic ovarian syndrome, gestational diabetes or steroid-induced diabetes, in any setting, during the measurement year or the year prior to the measurement year.
- Members receiving palliative care during the measurement year.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Statin Therapy for Patients with Cardiovascular Disease (SPC)



Description

The percentage of males 21-75 years of age and females 40-75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria.

1. *Received Statin Therapy.* Members who were dispensed at least one high-intensity or moderate-intensity statin medication (Table 4) during the measurement year.
2. *Statin Adherence 80%.* Members who remained on a high-intensity or moderate-intensity statin medication (Table 4) for at least 80% of the treatment period.

Eligible Population

Male members 21-75 years of age and women members 40-75 years of age during the measurement year with continuous enrollment of no more than one gap in enrollment of up to 45 days.

Event/Diagnosis

Members 21-75 (males) years of age and members 40-75 (women) years of age diagnosed with clinical atherosclerotic cardiovascular disease (ASCVD) and prescribed a high-intensity or moderate-intensity statin medication.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The Eligible Population (Member must have BCBSKS Medical and Pharmacy benefits)

Numerator

The number of members who had at least one dispensing event for a high-intensity or moderate-intensity statin medication during the measurement year.

Required Exclusions/ Negative Conditions

- Exclude members from the eligible population with a diagnosis of pregnancy, dispensed at least one prescription for clomiphene, ESRD, Cirrhosis, Myalgia, Myositis, Myopathy, Rhabdomyolysis as well as those members undergoing dialysis or in vitro fertilization.
- For those members ages 66 and higher, exclude those with a diagnosis of frailty accompanied with an inpatient stay or nonacute inpatient stay.
- Members receiving palliative care during the measurement year.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Table 4: High- and Moderate-Intensity Statin Medications

Description	Prescription
High-intensity statin therapy	• Atorvastatin 40-80 mg • Amlodipine-atorvastatin 40-80 mg • Ezetimibe-simvastatin 80 mg • Rosuvastatin 20-40 mg • Simvastatin 80 mg
Moderate-intensity statin therapy	• Atorvastatin 10-20 mg • Amlodipine-atorvastatin 10-20 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg • Ezetimibe-simvastatin 20-40 mg • Pravastatin 40-80 mg • Lovastatin 40 mg • Fluvastatin 40-80 mg bid • Pitavastatin 1-4 mg

Statin Therapy for Patients with Diabetes (SPD)



Description

The percentage of members 40-75 years of age during the measurement year with diabetes who do not have atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one statin medication (Table 5) of any intensity during the measurement year.

1. *Received Statin Therapy.* Members who were dispensed at least one statin medication of any intensity during the measurement year.
2. *Statin Adherence 80%.* Members who remained on a statin medication for at least 80% of the treatment period.

Eligible Population

The number of members aged 40-75 years during the measurement year with continuous enrollment of no more than one gap in enrollment of up to 45 days.

Event/Diagnosis

Members aged 40-75 years of age diagnosed with diabetes and prescribed a statin medication.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The Eligible Population (Member must have BCBSKS Medical and Pharmacy benefits)

Numerator

The number of members who had at least one dispensing event for a high-intensity, moderate intensity, or low-intensity statin medication during the measurement year.

Required Exclusions/ Negative Conditions

- Exclude those members who meet any of the following criteria: Members with Cardiovascular disease (identified by event or by diagnosis). **Event:** Any of the following during the year prior to the measurement year: 1. *MI* discharged from an inpatient setting with an MI on the discharge claim. Identify all acute and nonacute inpatient stays. 2. Identify the discharge date for the stay. Members who had CABG, PCI and Other Revascularization in any setting. **Diagnosis:** Identify members as having Ischemic Vascular Disease (IVD) and met at least of the following criteria during both the measurement year and the year prior: outpatient visits, or a telephone visit, or an e-visit or virtual check-in, or at least one acute inpatient encounter without telehealth or at least one acute inpatient discharge on the discharge claim. Identify an acute inpatient discharge: 1. Identify all acute and nonacute inpatient stays, 2. Exclude nonacute inpatient stays and 3. Identify the discharge date for the stay.
- Exclude members from the eligible population with a diagnosis of pregnancy, dispensed at least one prescription for clomiphene, ESRD, Cirrhosis, Myalgia, Myositis, Myopathy, Rhabdomyolysis as well as those members undergoing dialysis or in vitro fertilization.
- Members in hospice or using hospice services anytime during the measurement year.
- Members receiving palliative care during the measurement year.

Table 5: High- and Moderate-Intensity Statin Medications

Description	Prescription
High-intensity statin therapy	<ul style="list-style-type: none"> • Atorvastatin 40-80 mg • Amlodipine-atorvastatin 40-80 mg • Ezetimibe-simvastatin 80 mg • Rosuvastatin 20-40 mg • Simvastatin 80 mg
Moderate-intensity statin therapy	<ul style="list-style-type: none"> • Atorvastatin 10-20 mg • Amlodipine-atorvastatin 10-20 mg • Rosuvastatin 5-10 mg • Simvastatin 20-40 mg • Ezetimibe-simvastatin 20-40 mg • Pravastatin 40-80 mg • Lovastatin 40 mg • Fluvastatin 40-80 mg • Pitavastatin 1-4 mg
Low-intensity statin therapy	<ul style="list-style-type: none"> • Simvastatin 5-10 mg • Ezetimibe-simvastatin 10 mg • Pravastatin 10-20 mg • Lovastatin 10-20 mg • Fluvastatin 20 mg

Use of Imaging Studies for Low Back Pain (LBP)

Description

The percentage of members 18-75 years of age with a principal diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.

Calculation

The measure is reported as an inverted rate [1-(numerator/eligible population)]. A higher score indicates appropriate treatment of low back pain (i.e., the proportion for whom imaging studies did not occur).

Eligible Population

Members 18 years of age as of January 1 of the measurement year to members 75 years of age as of December 31 of measurement year with continuous enrollment of 180 days (6 months) prior to the IESD (no gaps in enrollment allowed during the continuous enrollment period) and with a primary diagnosis of low back pain.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

An imaging study with a diagnosis of uncomplicated low back pain on the IESD or in the 28 days following the IESD.

Required Exclusions/ Negative Conditions

A period of 180 days (6 months) prior to the IESD when the member had no claims/encounters with any diagnosis of low back pain.

Exclude any member who had a diagnosis for which imaging is clinically appropriate. Any of the following meet criteria:

- *Cancer.* Cancer any time during the member's history through 28 days after the IESD. Any of the following meet criteria: Malignant Neoplasms, Other Neoplasms, History of Malignant Neoplasm. And Other Malignant Neoplasm of Skin
- *Recent trauma.* Trauma any time during the 3 months (90 days) prior to the IESD through 28 days after the IESD.
- *Intravenous drug abuse.* IV drug abuse any time during the 12 months (1 year) prior to the IESD through 28 days after the IESD.
- *Neurologic Impairment.* Neurologic impairment any time during the 12 months (1 year) prior to the IESD through 28 days after the IESD.
- *HIV.* HIV any time during the member's history through 28 days after the IESD.
- *Spinal infection.* Spinal infection any time during the 12 months (1 year) prior to the IESD through 28 days after the IESD.
- *Major organ transplant.* Major organ transplant any time in the member's history through 28 days after the IESD.
- *Prolonged use of corticosteroids.* 90 consecutive days of corticosteroid treatment any time during the 366-day period that begins 365 days prior to the IESD and ends on the IESD.
- *Osteoporosis.* Osteoporosis therapy or a dispensed prescription to treat osteoporosis any time during the member's history through 28 days after the IESD
- *Fragility fracture.* Fragility fracture any time during the 3 months (90 days) prior to the IESD through 28 days after the IESD.
- *Lumbar surgery.* Lumbar surgery any time during the member's history through 28 days after the IESD.
- *Spondylopathy.* Spondylopathy any time during the member's history through 28 days after the IESD.
- *Palliative care.* Members receiving palliative care any time during the measurement year.
- *Members in hospice or using hospice services* anytime during the measurement year.
- *Members who died* any time during the measurement year.

Well-Child Visits in the First 30 Months of Life (W30)

Description

The percentage of members who had the following number of well-child visits with a PCP during the last 15 months. The following rates are reported:

1. Well-Child Visits in the First 15 Months. Children who turned 15 months during the measurement year: Six or more well-child visits.
2. Well-Child Visits for Age 15 Months-30 Months. Children who turned 30 months old during the measurement year: Two or more well-child visits.

Eligible Population

Children who turn 15 months old during the measurement year with continuous enrollment of no more than one gap in enrollment of up to 45 days from when turning 31 days of age to 15 months of age. Calculate the 15-month birthday as the child's first birthday plus 91 days.

Children who turn 30 months old during the measurement year with continuous enrollment from 15 months plus 1 day to 30 months of age with no more than 1 gap of up to 45 days. Calculate the 30-month birthday as the second birthday plus 180 days.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

Members who the following number of well-child visits with a PCP during the last 15 months.

1. Well-Child Visits in the First 15 Months: Children who turned 15 months old during the measurement year. Six or more well-child visits on different dates of service on or before the 15-month birthday.
2. Well-Child Visits for Age 15 Months-30 Months: Children who turned 30 months old during the measurement year. Two or more well-child visits on different dates of service between the child's 15-month birthday plus 1 day and the 30-month birthday.

The well-child visit must occur with a PCP, but the PCP does not have to be the practitioner assigned to the child.

Required Exclusions/ Negative Conditions

- Members in hospice or using hospice services anytime during the measurement year.
- Members who dies during the measurement period.

Child and Adolescent Well-Care Visits (WCV)



Description

The percentage of members 3–21 years of age who had at least one comprehensive well-care visit with a PCP or an OB/GYN practitioner during the measurement year.

Eligible Population

Children and adolescents ages 3-21 as of December 31 of the measurement year with continuous enrollment (no more than one gap in enrollment of up to 45 days in the measurement year).

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

- One or more well care visits during the measurement year.
- The well care visit must occur with a PCP or an OB/GYN practitioner, but the practitioner does not have to be the practitioner assigned to the member.

Required Exclusions/ Negative Conditions

- Members in hospice or using hospice services anytime during the measurement year.
- Member who dies at any time during the measurement period



Appendix A: Definitions

- Denominator - Eligible members of the population.
- Numerator - Members who met the criteria of a measure.
- HEDIS (Healthcare Effectiveness Data and Information Set) - Tool used by more than 90% of America's health plans to measure performance on important dimensions of care and service.
- Intake Period - The period of time (typically the measurement year) used to identify the first eligible encounter.
- Index Episode Start Date (IESD) - The earliest date of service for an eligible encounter during the intake period.
- Index Prescription Start Date (IPSD) - The date of the first fill for any target medication.
- Anchor Date - The specific date the member is required to be enrolled to be eligible for the measure.
- Measurement Year – The twelve-month timeframe of data used to support the calculation of the bi-annual QBRP performance scores. For BCBSKS' QBRP HEDIS-based performance scores, the Jan. 1 through Dec. 31 measurement year is used to support the July through Dec. 31 QBRP scores of the following bi-annual QBRP cycle, and the July 1 through June 30 measurement year is used to support the Jan. 1 through June 30 QBRP scores of the following bi-annual QBRP cycle.
- Continuous Enrollment - A period of time, during the measurement timeline, where a member must be enrolled in order to be counted towards the measure.
- Primary Care Physician (PCP) - A physician or non-physician (e.g., nurse practitioner, physician assistant) who offers primary care medical services. LPNs and RNs are not considered PCPs
- Episode Date - The date of service for any outpatient or ED visit during the intake period.

Appendix B: Changes

Version	Description	Effective Date
2018.v1	Initial Release	3/2017
2018.v2	Updated with new coding value sets and formatting changes.	6/2017
2019.v1	Updated to include 2019 QBRP measures including code sets. Added negative conditions to CWP, AAB, LBP.	7/2018
2019.v2	General updates to Title Page, AWC, CWP, CDC, CCS, LBP, and Appendix A.	10/2018
2020.v1	Updated with new coding value sets and addition of new measures. Added CPT II and ICD-10 'history of' codes where applicable. Removed LOINC code sets.	01/2019
2020.v2	Updated with addition of new measures CDC-EYE, CDC-NEPH, SPC, and SPD.	08/2019
2020.v3	Updated with specification changes for HEDIS 2020 and coding set updates. Changes include: <ul style="list-style-type: none"> • CWP- Expanded age range from 3-18 years of age to 3 years of age and older. • URI- Expanded age range from 3 months-18 years of age (children) to 3 months of age and older. • AAB- Expanded age range from 18-64 years of age (adults) to members 3 months of age and older • CCS- Updated screening methods to include primary high-risk human papillomavirus testing. 	08/2020
2022.v1	Updated measure set to remove AWC, CDC-NEPH, W15, W34, SPC-80%, SPD-80% and replaced with W30 (2 rates), WCV, SPD-Received Statin Therapy, SPC- Received Statin Therapy. Updated value code sets. Added Appendix C: Supplemental Code Sets Added Appendix D: Potential Future Changes Changed Appendix B 'Dates' to 'Effective Date'	01/2022
2023.v1	Updated with specification changes for HEDIS 2023 and coding set updates: The following changes was made: <ul style="list-style-type: none"> • CDC-Split into two measures <ul style="list-style-type: none"> • EED -Eye Exam for Patients with Diabetes • HBD -Hemoglobin A1C for Patients with Diabetes Updated value code sets and medication list. Updated Appendix C: Supplemental Code Sets (added additional codes) Added Appendix E: Stratification by Race and Ethnicity	08/2022
2023.v2	Updated with specification changes for HEDIS 2023 and coding set updates: The following changes were made: <ul style="list-style-type: none"> • BCS will be reported as BCS-E in 2023. HEDIS measures reported using Electronic Clinical Data Systems (ECDS) includes all members who satisfy criteria, including age and participation criteria. • Created a separate excel document to list HEDIS value sets. • Updated required exclusion reason on multiple measures. • Added medication list for Asthma and Antidepressants 	

Appendix C: Supplemental Code Sets – Z Codes and CPT Category II Codes

BCBSKS is promoting the use of ICD-10 Z codes and CPT Category II code sets. By using these codes, BCBSKS can better identify Social Determinants of Health, history of mastectomy, hysterectomy and colectomy, and lab result codes which will ultimately result in the reduction of medical record requests.

ICD-10 Z Codes

Social Determinant	ICD-10-CM Code/Description	
Problems related to education and literacy (Z55)	Z55.0 Illiteracy and low-level literacy Z55.1 Schooling unavailable and unattainable Z55.2 Failed school examinations Z55.3 Underachievement in school	Z55.4 Educational maladjustment and discord with teachers and classmates Z55.8 Other problems related to education and literacy Z55.9 Problems related to education and literacy, unspecified
Problems related to employment and unemployment (Z56)	Z56.0 Unemployment, unspecified Z56.1 Change of Job Z56.2 Threat of job loss Z56.3 Stressful work schedule Z56.4 Discord with boss and workmates Z56.5 Uncongenial work environment	Z56.6 Other physical and mental strain related to work Z56.81 Sexual harassment on the job Z56.82 Military deployment status Z56.89 Other problems related to employment Z56.9 Unspecified problems related to employment
Occupational exposure to risk factors (Z57)	Z57.0 Occupational exposure to noise Z57.1 Occupational exposure to radiation Z57.2 Occupational exposure to dust Z57.31 Occupational exposure to environmental tobacco smoke Z57.39 Occupational exposure to other air contaminants Z57.4 Occupational exposure to toxic agents in agriculture	Z57.5 Occupational exposure to toxic agents in other industries Z57.6 Occupational exposure to extreme temperature Z57.7 Occupational exposure to vibration Z57.8 Occupational exposure to other risk factors Z57.9 Occupational exposure to unspecified risk factor

ICD-10 Z Codes

Social Determinant	ICD-10-CM Code/Description	
Problems related to housing and economic circumstances (Z59)	Z59.0 Homelessness Z59.1 Inadequate housing Z59.2 Discord with neighbors, lodgers, and landlord Z59.3 Problems related to living in residential institution Z59.4 Lack of adequate food and safe drinking water Z59.5 Extreme poverty Z59.6 Low income	Z59.7 Insufficient social insurance and welfare support Z59.8 Other problems related to housing and economic circumstances Z59.9 Problem related to housing and economic circumstances, unspecified
Problems related to social environment (Z60)	Z60.0 Problems of adjustment to life-cycle transitions Z60.2 Problems related to living alone Z60.3 Acculturation difficulty Z60.4 Social exclusion and rejection	Z60.5 Target of (perceived) adverse discrimination and persecution Z60.8 Other problems related to social environment Z60.9 Problems related to social environment, unspecified
Problems related to upbringing (Z62)	Z62.0 Inadequate parental supervision and control Z62.1 Parental overprotection Z62.21 Child in welfare custody Z62.22 Institutional upbringing Z62.29 Other upbringing away from parents Z62.3 Hostility towards and scapegoating of child Z62.6 Inappropriate (excessive) parental pressure Z62.810 Personal history of physical and sexual abuse in childhood Z62.811 Personal history of psychological abuse in childhood	Z62.812 Personal history of neglect in childhood Z62.813 Personal history of forced labor or sexual exploitation in childhood Z62.819 Personal history of unspecified abuse in childhood Z62.820 Parent-biological child conflict Z62.821 Parent-adopted child conflict Z62.822 Parent-foster child conflict Z62.890 Parent-child estrangement NEC Z62.891 Sibling rivalry Z62.898 Other specified problems related to upbringing

ICD-10 Z Codes

Social Determinant	ICD-10-CM Code/Description	
Other problems related to primary support group, including family circumstances (Z63)	Z63.0 Problems in relationship with spouse or partner Z63.1 Problems in relationship with in-laws Z63.31 Absence of family member due to military deployment Z63.32 Other absence of family member Z63.4 Disappearance and death of family member Z63.5 Disruption of family by separation and divorce Z63.6 Dependent relative needing care at home	Z63.71 Stress on family due to return of family member from military deployment Z63.72 Alcoholism and drug addiction in family Z63.79 Other stressful life events affecting family and household Z63.8 Other specified problems related to primary support group Z63.9 Problem related to primary support group, unspecified
Problems related to certain psychosocial circumstances (Z64)	Z64.0 Problems related to unwanted pregnancy Z64.1 Problems related to multiparity	Z64.4 Discord with counselor
Problems related to upbringing (Z62)	Z62.0 Inadequate parental supervision and control Z62.1 Parental overprotection Z62.21 Child in welfare custody Z62.22 Institutional upbringing Z62.29 Other upbringing away from parents Z62.3 Hostility towards and scapegoating of child Z62.6 Inappropriate (excessive) parental pressure Z62.810 Personal history of physical and sexual abuse in childhood Z62.811 Personal history of psychological abuse in childhood	Z62.812 Personal history of neglect in childhood Z62.813 Personal history of forced labor or sexual exploitation in childhood Z62.819 Personal history of unspecified abuse in childhood Z62.820 Parent-biological child conflict Z62.821 Parent-adopted child conflict Z62.822 Parent-foster child conflict Z62.890 Parent-child estrangement NEC Z62.891 Sibling rivalry Z62.898 Other specified problems related to upbringing

ICD-10 Z Codes

Social Determinant	ICD-10-CM Code/Description	
Other problems related to primary support group, including family circumstances (Z63)	Z63.0 Problems in relationship with spouse or partner Z63.1 Problems in relationship with in-laws Z63.31 Absence of family member due to military deployment Z63.32 Other absence of family member Z63.4 Disappearance and death of family member Z63.5 Disruption of family by separation and divorce Z63.6 Dependent relative needing care at home	Z63.71 Stress on family due to return of family member from military deployment Z63.72 Alcoholism and drug addiction in family Z63.79 Other stressful life events affecting family and household Z63.8 Other specified problems related to primary support group Z63.9 Problem related to primary support group, unspecified
Problems related to certain psychosocial circumstances (Z64)	Z64.0 Problems related to unwanted pregnancy Z64.1 Problems related to multiparity	Z64.4 Discord with counselor
Problems related to other psychosocial circumstances (Z65)	Z65.0 Conviction in civil and criminal proceedings without imprisonment Z65.1 Imprisonment and other incarceration Z65.2 Problems related to release from prison Z65.3 Problems related to other legal circumstances Z65.4 Victim of crime and terrorism	Z65.5 Exposure to disaster, war, and other hostilities Z65.8 Other specified problems related to psychosocial circumstances Z65.9 Problem related to unspecified psychosocial circumstances
Problems related to medical facilities and other health care (Z75)	Z75.0 Medical services not available at home Z75.1 Person awaiting admission to adequate facility elsewhere Z75.2 Other waiting period for investigation and treatment Z75.3 Unavailability and inaccessibility of health care facilities Z75.4 Unavailability and inaccessibility of other helping agencies	Z75.5 Holiday relief care Z75.8 Other problems related to medical facilities and other health care Z75.9 Unspecified problem related to medical facilities and other health care

This list should not be considered comprehensive of all available codes. The codes listed are those commonly used codes.

Other ICD-10CM Z Codes for HEDIS®

Diagnosis/Condition	ICD-10-CM Code/Description	
History of Bilateral Mastectomy	Z90.13 Acquired absence of bilateral breasts and nipples	
Absence of Cervix Diagnosis	Z90.710 Acquired absence of both cervix and uterus	Z90.712 Acquired absence of cervix with remaining uterus
Pregnancy Diagnosis	Z03.71 Encounter for suspected problem with amniotic cavity and membrane ruled out Z03.72 Encounter for suspected placental problem ruled out Z03.73 Encounter for suspected fetal anomaly ruled out Z03.74 Encounter for suspected problem with fetal growth ruled out Z03.75 Encounter for suspected cervical shortening ruled out Z03.79 Encounter for other suspected maternal and fetal conditions ruled out Z32.01 Encounter for pregnancy test, result positive Z34.00 Encounter for supervision of normal first pregnancy, unspecified trimester Z34.01 Encounter for supervision of normal first pregnancy, first Trimester Z34.02 Encounter for supervision of normal first pregnancy, second trimester Z34.03 Encounter for supervision of normal first pregnancy, third trimester	Z34.80 Encounter for supervision of other normal pregnancy, unspecified trimester Z34.81 Encounter for supervision of other normal pregnancy, first trimester Z34.82 Encounter for supervision of other normal pregnancy, second trimester Z34.83 Encounter for supervision of other normal pregnancy, third trimester Z34.90 Encounter for supervision of normal pregnancy, unspecified, unspecified trimester Z34.91 Encounter for supervision of normal pregnancy, unspecified, first trimester Z34.92 Encounter for supervision of normal pregnancy, unspecified, second trimester Z34.93 Encounter for supervision of normal pregnancy, unspecified, third trimester Z36.0 Encounter for antenatal screening of mother
Postpartum Care	Z39.2 Encounter for routine postpartum follow-up	Z39.1 Encounter for care and examination of lactating mother

CPT-II Codes

Measure	CPT-II Code	Description
PPC	0500F	Initial prenatal care visit (report at first prenatal encounter with health care professional providing obstetrical care. Report also date of visit and, in a separate field, the date of the last menstrual period [LMP]) (Prenatal)
PPC	0501F	Prenatal flow sheet documented in medical record by first prenatal visit (documentation includes at minimum blood pressure, weight, urine protein, uterine size, fetal heart tones, and estimated date of delivery). Report also: date of visit and, in a separate field, the date of the last menstrual period [LMP] (Note: If reporting 0501F Prenatal flow sheet, it is not necessary to report 0500F Initial prenatal care visit) (Prenatal)
PPC	0502F	Subsequent prenatal care visit (Prenatal) [Excludes: patients who are seen for a condition unrelated to pregnancy or prenatal care (eg, an upper respiratory infection; patients seen for consultation only, not for continuing care)]
PPC	0503F	Postpartum care visit (Prenatal)
EED	2022F	Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM)
EED	2023F	Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)
EED	2024F	Seven standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed: with evidence of retinopathy (DM)
EED	2025F	Seven standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed: without evidence of retinopathy (DM)
EED	2026F	Eye imaging validated to match diagnosis from seven standard field stereoscopic retinal photos results documented and reviewed: with evidence of retinopathy (DM)
EED	2033F	Eye imaging validated to match diagnosis from seven standard field stereoscopic retinal photos results documented and reviewed: without evidence of retinopathy (DM)
EED	3072F	Low risk for retinopathy (no evidence of retinopathy in the prior year) (DM)

CPT-II Codes

Measure	CPT-II Code	Description
HBD	3044F	Most recent hemoglobin A1c (HbA1c) level less than 7.0% (DM)
HBD	3046F	Most recent hemoglobin A1c level greater than 9.0% (DM)
HBD	3051F	Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM)
HBD	3052F	Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0% and less than or equal to 9.0% (DM)
CBP	3074F	Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD)
CBP	3075F	Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD)
CBP	3077F	Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM)
CBP	3078F	Most recent diastolic blood pressure less than 80 mm Hg
CBP	3079F	Most recent diastolic blood pressure 80-89 mm Hg
CBP	3080F	Most recent diastolic blood pressure greater than or equal to 90 mm Hg
MRP	1111F	Discharge medications reconciled with the current medication list in outpatient medical record (COA) (GER)

This list should not be considered comprehensive of all available codes. The codes listed are those commonly used codes.

Appendix D: Potential Future Measures

These potential measure additions are being communicated as possible changes that may be in the coming year. This will allow providers to become educated on the measures prior to being implemented into QBRP.

Antidepressant Medication Management (AMM)

Description

The percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment. Two rates are reported.

1. *Effective Acute Phase Treatment.* The percentage of members who remained on an antidepressant medication for at least 84 days (12 weeks).
2. *Effective Continuation Phase Treatment.* The percentage of members who remained on an antidepressant medication for at least 180 days (6 months).

Eligible Population

Members 18 years and older as of April 30 of the measurement year with continuous enrollment of 105 days prior to the IPSD through 231 days after the IPSD. Only one gap in enrollment of up to 45 days.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population. (Member must have BCBSKS Medical and Pharmacy benefits)

Numerator

- At least 84 days (12 weeks) of treatment with antidepressant medication (Table 6), beginning on the IPSD through 114 days after the IPSD (115 total days). This allows gaps in medication treatment up to a total of 31 days during the 115-day period. Gaps can include either washout period gaps to change medication or treatment gaps to refill the same medication.

Required Exclusions/ Negative Conditions

- Exclude members who did not have an encounter with a diagnosis of major depression during the 121-day period from 60 days prior to the IPSD, through the IPSD and the 60 days after the IPSD.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died during the measurement period.

Table 6: Antidepressant Medications

Description	Prescription
Miscellaneous antidepressants	• Bupropion • Vilazodone • Vortioxetine
Monoamine oxidase inhibitors	• Isocarboxazid • Phenelzine • Selegiline • Tranylcypromine
Phenylpiperazine antidepressants	• Nefazodone • Trazodone
Psychotherapeutic combinations	• Amitriptyline-chlordiazepoxide • Amitriptyline-perphenazine • Fluoxetine-olanzapine
SNRI antidepressants	• Desvenlafaxine • Duloxetine • Levomilnacipran • Venlafaxine
SSRI antidepressants	• Citalopram • Escitalopram • Fluoxetine • Fluvoxamine • Paroxetine • Sertraline
Tetracyclic antidepressants	• Maprotiline • Mirtazapine
Tricyclic antidepressants	• Amitriptyline • Amoxapine • Clomipramine • Desipramine • Doxepin (>6 mg) • Imipramine • Nortriptyline • Protriptyline • Trimipramine

Asthma Medication Ratio (AMR)

Description

The percentage of members 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

Eligible Population

Members ages 5-64 as of December 31 of the measurement year with continuous enrollment (no more than one gap in enrollment of up to 45 days in the measurement year).

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Denominator

The eligible population.

Numerator

The number of members who have a medication ratio of 0.50 or greater during the measurement year. Follow the steps below to calculate the ratio.

Use all the medication lists in the Asthma Controller Medications (Table 7) to identify asthma controller medications. Use all the medication lists in the Asthma Reliever Medications (Table 7) to identify asthma reliever medications.

Step 1- For each member, count the units of asthma controller medications dispensed during the measurement year.

Step 2- For each member, count the units of asthma reliever medications dispensed during the measurement year.

Step 3- For each member, sum the units calculated in step 1 and step 2 to determine units of total asthma medications.

Step 4- For each member, calculate the ratio of controller medications to total asthma medications using the following formula. Round (using the .5 rule) to the nearest whole number.

$$\frac{\text{Units of Controller Medications (Step 1)}}{\text{Units of Total Asthma Medications (Step 3)}}$$

Step 5- Sum the total number of members who have a ratio of 0.50 or greater in step 4.

Required Exclusions/ Negative Conditions

- Exclude members with the following diagnosis: Emphysema, COPD, Obstructive Chronic Bronchitis, Chronic Respiratory Conditions due to Fumes, Cystic Fibrosis, Acute Respiratory Failure.
- Exclude members who had no asthma controller or reliever medications dispensed during the measurement year.
- Exclude members in hospice or using hospice services anytime during the measurement year.
- Exclude members who died anytime during the measurement year.

Table 7: Asthma Medications

Description	Prescription
Controller Medications	• Omalizumab • Dupilumab • Benralizumab • Mepolizumab • Reslizumab • Budesonide-formoterol • Fluticasone-salmeterol • Fluticasone-vilanterol • Formoterol-mometasone • Beclomethsone • Budesonide • Ciclesonide • Flunisolide • Mometasone • Montelukast • Zafirlukast • Zileuton • Theophylline
Reliever Medications	• Albuterol • Levalbuterol

Follow-up after Emergency Department Visit for Substance Use (FUA)



Description

The percentage of emergency department (ED) visits among members age 13 years and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up. Two rates are reported:

1. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
2. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

Eligible Population

Members aged 13 and older as of the ED visit with a continuous enrollment of the date of the ED visit through 30 days after the ED visit.

Denominator

The eligible population.

Numerator

1. A follow-up visits or a pharmacotherapy dispensing event within 30 days after the ED visit (31 total days). Include visits and pharmacotherapy events that occur on the date of the ED visit.
2. A follow-up visit or a pharmacotherapy dispensing event within 7 days after the ED visit (8 total days). Include visits and pharmacotherapy events that occur on the date of the ED visit

Coding!

[Click here to go to the Coding and Value Set Guide](#)

Required Exclusions/ Negative Conditions

- Exclude ED visits that result in an inpatient stay and ED visits followed by an admission to an acute or nonacute inpatient care setting on the date of the ED visit or within the 30 days after the ED visit, regardless of the principal diagnosis for the admission. To identify admissions to an acute or nonacute inpatient care setting:
 - Identify all acute and nonacute inpatient stays.
 - Identify the admission date for the stay.These events are excluded from the measure because admission to an acute or nonacute inpatient setting may prevent an outpatient follow-up visit from taking place.
- Exclude members who meet either of the following criteria:
 - Members in hospice or using hospice services anytime during the measurement year.
 - Members who died any time during the measurement year.

Follow-up after Emergency Department Visit for Mental Illness (FUM)



Description

The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness. Two rates are reported:

1. The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days).
2. The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days).

Eligible Population

Members aged 6 and older as of the ED visit with a continuous enrollment of the date of the ED visit through 30 days after the ED visit.

Denominator

The eligible population.

Numerator

1. A follow-up visit with any practitioner, with a principal diagnosis of a mental health disorder or with a principal diagnosis of intentional self-harm and any diagnosis of a mental health disorder within 30 days after the ED visit (31 total days).
Include visits that occur on the date of the ED visit.
2. A follow-up visit with any practitioner, with a principal diagnosis of a mental health disorder or with a principal diagnosis of intentional self-harm and any diagnosis of a mental health disorder within 7 days after the ED visit (8 total days).
Include visits that occur on the date of the ED visit.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Required Exclusions/Negative Conditions

- Exclude ED visits that result in an inpatient stay and ED visits followed by an admission to an acute or nonacute inpatient care setting on the date of the ED visit or within the 30 days after the ED visit, regardless of the principal diagnosis for the admission.
- To identify admissions to an acute or nonacute inpatient care setting:
 - Identify all acute and nonacute inpatient stays.
 - Identify the admission date for the stay.
- These events are excluded from the measure because admission to an acute or nonacute inpatient setting may prevent an outpatient follow-up visit from taking place.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Follow-up after Hospitalization for Mental Illness (FUH)



Description

The percentage of discharges for members 6 years of age and older who were hospitalized for treatment of selected mental illness or intentional self-harm diagnoses and who had a follow-up visit with a mental health provider. Two rates are reported:

1. The percentage of discharges for which the member received follow-up within 30 days after discharge.
2. The percentage of discharges for which the member received follow-up within 7 days after discharge.

Eligible Population

Members aged 6 and older as of the date of discharge with a continuous enrollment of the date of discharge through 30 days after discharge.

Denominator

The eligible population.

Numerator

1. A follow-up visit with a mental health provider within 30 days after discharge. Do not include visits that occur on the date of discharge.
2. A follow-up visit with a mental health provider within 7 days after discharge. Do not include visits that occur on the date of discharge.

Coding¹

[Click here to go to the Coding and Value Set Guide](#)

Required Exclusions/Negative Conditions

- Exclude discharges followed by readmission or direct transfer to a nonacute inpatient care setting within the 30-day follow-up period, regardless of principal diagnosis for the readmission.
- To identify readmissions and direct transfers to a nonacute inpatient care setting:
 - Identify all acute and nonacute inpatient stays.
 - Confirm the stay was for nonacute care based on the presence of a nonacute code on the claim.
 - Identify the admission date for the stay.
- These discharges are excluded from the measure because rehospitalization or direct transfer may prevent an outpatient follow-up visit from taking place.
- Members in hospice or using hospice services anytime during the measurement year.
- Members who died any time during the measurement year.

Appendix E: Stratifications by Race and Ethnicity

Race	Ethnicity
<ul style="list-style-type: none"> • White • Black or African American • American Indian and Alaska Native • Asian • Native Hawaiian and Other Pacific Islander • Some Other Race • Two or More Races • Asked but No Answer • Unknown 	<ul style="list-style-type: none"> • Hispanic/Latino • Not Hispanic/Latino • Asked but No Answer • Unknown

Measures reporting Race and Ethnicity Stratifications	
COL	Colorectal Cancer Screening
CBP	Controlling High Blood Pressure
HBD	Hemoglobin A1c Control Patients with Diabetes
PPC	Prenatal and Postpartum Care
WCV	Child and Adolescent Well-Care Visits

HEDIS Copyright Notice and Disclaimer

The HEDIS® measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA ©2022 NCQA, all rights reserved.

Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications.

The American Medical Association holds a copyright to the CPT® codes contained in the measure specifications. CPT Copyright 2022 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

The American Hospital Association holds a copyright to the Uniform Billing Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. The UB Codes contained in the HEDIS specifications may be used by health plans and other health care delivery organizations for the purpose of calculating and reporting HEDIS measure results or using HEDIS measure results for their internal quality improvement purposes. All other uses of the UB Codes require a license from the AHA. Anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@aha.org.



bcbsks.com

Quality-Based Reimbursement Program